Officials at the US Department of Health and Human Services, which awarded funding for the controversial study, say it will ...
The U.S. also endured its highest flu-related hospitalization rates in almost 15 years last flu season, with unvaccinated ...
A vaccine developed to tackle Streptococcus suis, an economically damaging disease endemic in the global pig population, has ...
Nirsevimab may offer infants stronger protection against severe respiratory syncytial virus than maternal vaccination, ...
Confused about childhood vaccines in 2026? This expert-backed guide explains what shots your child needs, when they need them, how schedules have changed, and what today’s political climate means for ...
Sanofi's acquisition of Dynavax, valued at $2.2 billion, aims to enhance its vaccine portfolio, including a promising shingles vaccine candidate, Z-1018. Z-1018 has demonstrated comparable ...
COVID-19, RSV, and influenza immunizations show continued safety and substantial effectiveness against hospitalization across ...
DOHA: The Ministry of Public Health (MoPH) has urged those most at risk to receive the Respiratory Syncytial Virus (RSV) ...
Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or ...
A trial was about to launch for a vaccine that would ward off the HIV virus. It would be an incredible breakthrough. Then it ...
Health and Me on MSNOpinion
RSV vaccine has benefits, reveals study amid CDC's changed guidelines on childhood vaccines
RSV is a leading cause of infant hospitalizations, but prevention shots approved in 2023 have sharply reduced severe illness.
The analysis of samples containing Respiratory Syncytial Virus (RSV) in clinical trials is notoriously challenging due to the virus's inherent instability. hVIVO’s proprietary Stabilization Transport ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results